In this work multiwalled carbon nanotube (MWCNT)/fibrin hybrid structures were synthesized via the transglutaminase-catalyzed polymerization of fibrinogen (FBG). Specifically, FBG was tethered onto oxidized MWCNTs by amide coupling, and the in situ polymerization of FBG to fibrin was performed by plasma transglutaminase (Factor XIIIa) in the presence of thrombin. The attached FBG was found to be biologically active and was polymerized to fibrin by thrombin and Factor XIIIa. MWCNT-FBG and MWCNT-Fibrin structures were characterized by FT-IR spectroscopy, transmission electron microscopy, and energy-dispersive X-ray (EDX) spectroscopy.
Introduction
Carbon nanotubes (CNTs) possess many interesting and unique properties. They are found in everyday applications, such as field emission displays, energy storage devices, nanoelectronics and scaffolds for tissue engineering. [1] [2] [3] [4] [5] Recently, the unique properties of CNTs have been utilized in biological and biomedical devices. They have been employed in a variety of drug and gene delivery systems, and anticancer treatments. [6] [7] [8] Various methods for functionalizing CNTs with organic and inorganic materials or biomolecules, such as peptides, DNA and proteins have been recently reported. [9] [10] [11] [12] In this study, fibrinogen (FBG) was selected as a potential protein for conjugation to CNTs. As an acute phase defensive plasma glycoprotein FBG acts as a core entity in the final phase of blood coagulation. 13, 14 The main function of FBG is the polymerization of a three-dimensional network of fibrin fibers. 13, 14 FBG plays a role in cancer and tumor growth, [15] [16] [17] [18] cell migration 19 ,20 cellular differentiation [21] [22] [23] and platelet regulation. 24, 25 In addition FBG fragments (D-Dimer) act as markers for various cardiovascular diseases. 26, 27 Even though high concentrations of FBG exist in blood (~3 mg/mL), FBG monomers are inert, polymerized by the thrombin and others co-factors involved in the regulation of the transglutaminase pathway. 28, 29 In this paper the free amine groups of FBG and the carboxylic acid groups on the ends and sidewalls of oxidized multiwalled carbon nanotubes (MWCNTs) were crosslinked to each other via an EDC based coupling reaction. The functionalized bio-nanotubes were polymerized using the for-mentioned pathway forming a novel bio-composite material, the properties of which have been highlighted and discussed within.
Experimental Section
Materials. Multiwalled carbon nanotubes (MWCNTs, 10-25 nm in diameter, 10-50 m in length, produced by the CVD process) were purchased from Iljin Nanotech, and were used as received. Fibrinogen (F 3879) and thrombin (T 4393) were purchased from Sigma Inc. Plasma transglutaminase (FXIII, HCXIII-0160) was purchased from Haemtech, Inc. Imject Immunogen EDC Conjugation Kits was purchased from Pierce Biotech, Inc. Fibrin polymerization inhibitor, H-Gly-Pro-Arg-Pro-NH2, (GPRP, H-1998) was purchased from Bachem, Inc.
Characterization. Transmission electron microscopy (TEM) images were recorded with a Hitachi H-7600 microscope at 100 kV. Energy dispersion of X-ray spectroscopy (EDX) coupled with TEM was performed with a JEM-2010 electron microscope JEOL HIGHTECH at 120 kV. 
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Results and Discussion
The amide bond between fibrinogen and MWCNT-COOH was formed using an EDC-based coupling reaction, which cross-linked the carboxyl and amine groups. EDC reacted with a carboxyl group on MWCNTs, forming an amine reactive intermediate. This intermediate may react with an amine group of Lys in FBG, yielding a conjugate of the two entities, joined by a stable amide covalent bond. Fibrin polymerization inhibitor, GPRP, was added to the FBG solution. GPRP could bind into the polymerization pocket of the activated fibrin, preventing any unwanted polymerization reaction during the conjugation of fibrinogen onto MWCNTs, and keeping FBG as monomer. Activated Factor XIII (Factor XIIIa) stabilized the blood clot by cross-linking fibrin monomers between Lys and Gln residues, especially in a-and g-chains of fibrin, in the final stages of the coagulation cascade. As only non-proteolytic enzyme of the coagulation cascade, Factor XIII belonged to a family of transglutaminase. In plasma, Factor XIII existed as a tetramer (Mw = 320,000), where two pairs of subdomain (A2B2) are held together by noncovalent bonds. 28 Thrombin activates the zymogen Factor XIII to the active form Factor XIIIa by removing ~4000 MW fragment from the NH2-terminals of both A chains. The full activity of Factor XIIIa can be gained by addition of CaCl 2 , where the catalytic activity is located in the A subunits. The A subunit contains 6 free sulfhydryl groups one of which was the active site. 29 Among the transglutaminase family, only plasma Factor XIII exists as zymogen in vivo. Factor XIIIa increases the stability, insolubility, elasticity and its resistance against lysis of the clot. EDX coupled with TEM, measuring the atomic composition, was used to analyze the elements of the dark spots shown in Figure 1(c) . Figure 2 shows the TEM-EDX analysis of MWCNT-FBG (a) and MWCNT-Fibrin (b). The relative intensity of calcium was increased after the polymerization. This result indicated that the element of the dark spots might be calcium, which was used in the polymerization of MWCNT-Fibrin. (amideⅡ) in the spectra of . After the polymerization, we observed that the intensity of the peak of fibrinogen increased around 1689cm -1 due to the increase of β-sheets (3b). The increase of β-sheets in fibrin after the polymerization with respect to FBG molecule were due to the increased formation of intramolecular and intermolecular β-sheets from the conformational changes of the staggered overlapping fibrillar array and their lateral association. 31 The increase in the peak intensity, the signature bands of FBG, the TEM images of cross-linked fibrin, and increased β-sheet content, indicate that FBG retained a significant degree of biological function when immoblised to the carbon nanotubes. It raises the possibility that such material could be used in a coagulation reaction.
In addition enzymes involved in coagulation, such as thrombin, FBG, and Factor XIII, could create barriers or sheet-like structures through the formation of fibrin networks. These networks in turn could be degraded in a safe and controlled manner by other enzymes, moreover such processes does not use strong acid and alkalis and might be considered as alternative to modern day microfabrication processes. In addition these types of materials could be incorporated in new types of integrated biosensors and bio-compatible single cell based detectors.
Conclusions
In this study, the enzymatic polymerization of MWCNT-FBG to MWCNT-Fibrin by thrombin and Factor XIII was completed. The process consisted of two simple steps, the conjugation of FBG with MWCNTs, followed by the in situ enzymatic polymerization of MWCNT-FBG to MWCNT-Fibrin. In spite of chemical attachment of FBG to MWCNTs, FBG maintained its biological polymerization property. Since FBG could be dissolved easily in aqueous solution and fibrin can be degraded by plasmin. It might also be possible to generate new types of CNTs structures. These results highlight the potential applications of both FBG and MWCNTs.
